biopharmaceutical

$GLSI receives Nasdaq compliance notice for late Form 10-K filing; stock remains tradable as company works with auditors on submission.

Inventiva appoints three senior executives to strengthen leadership before Phase 3 lanifibranor data readout expected Q4 2026.

Madrigal Pharmaceuticals reports Q1 2026 results May 6, revealing early commercial performance of FDA/EMA-approved MASH treatment Rezdiffra following recent regulatory clearances.

Cytokinetics will report Q1 2026 earnings May 5, discussing MYQORZO® commercialization and pipeline progress in heart failure treatments.

GENFIT published 2025 extra-financial report, achieving B Corp certification and executing 30 ESG initiatives with strong employee engagement and gender equality metrics.

GENFIT earns B Corp certification and implements 30+ ESG initiatives, achieving 90% employee engagement and maintaining gender equality index of 88.

Global life sciences consulting market projected to reach $29.6B by 2034 from $14.1B in 2024, driven by AI adoption and biotech expansion.

Royalty Pharma declares $0.235 per share dividend for Q2 2026, reinforcing its cash-generative business model across 35+ pharmaceutical products.

Immuron reports Q3 sales of AUD$1.5M, up 16% YoY, with explosive 82% growth in Canada offsetting modest USA expansion.

Trevi Therapeutics prices $150M stock offering at $13/share, raising capital for Haduvio development across chronic cough indications.

Trevi Therapeutics raises $150M via stock offering at $13/share to fund development of Haduvio for idiopathic pulmonary fibrosis-related cough.

CDT Equity shares rallied 14.71% to $4.68 Monday despite widening $39.1M losses and late 10K filing, defying sector decline.

Geron appoints Timothy Williams as Chief Legal Officer and EVP, strengthening management amid commercial expansion in blood cancer treatments.

Viking Therapeutics to present at two major biotech conferences in April 2026, conducting investor meetings in New York and Boston.

Telix Pharmaceuticals appoints two Non-Executive Directors: former Pfizer CMO Maria Rivas and corporate finance leader William Jellison, effective May 2026.

Inventiva filed 2025 regulatory documents with €99.3M cash on hand, advancing lanifibranor Phase 3 trial for metabolic liver disease treatment.

Inventiva filed 2025 regulatory documents showing €230.9M cash reserves and €4.5M revenues while advancing lanifibranor in Phase 3 MASH trials.

Ascendis Pharma to convert ADS shares to direct Nasdaq listing on 1:1 basis effective April 2026, aiming to expand investor access and index eligibility.

$CBPO secures $7.5M milestone from Boehringer Ingelheim partnership, with $337.5M upside potential as lead compound advances to optimization.

Arcutis director sells 10,000 shares via pre-planned trading arrangement as stock surges 65%. ZORYVE revenue hit $372.1M in 2025, up 123% YoY, with company achieving positive operating cash flow.